{"ticker": {"uuid": "57c99d55-6f56-41ab-8d52-0f601d97cc61", "symbol": "VOR", "name": "Vor Biopharma Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Vor Biopharma (VOR) Stock Forum and Discussion", "summary": "This article provides a platform for discussion regarding Vor Biopharma (VOR) stock. It includes a basic overview of the company's stock performance and related financial metrics, along with sections for forum discussions, price forecasts, and news. The content primarily serves a", "url": "https://www.moomoo.com/stock/VOR-US/community?chain_id=Name1K9-3FXPhg.1kuar40&global_content=%7B%22promote_id%22%3A14282,%22sub_promote_id%22%3A29,%22f%22%3A%22www.moomoo.com%2Fca%2Fhans%2Flearn%2Fdetail-buy-call-66283-230283080%22%7D", "source_name": "Moomoo", "published_at": "2026-07-15T00:21:00", "published_display": "15 Jul 2026 00:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Vor Biopharma Inc. (VOR) Stock Price | Live Quotes & Charts | NASDAQ", "summary": "This page provides live quotes and charts for Vor Biopharma Inc. (VOR) stock, showing its current price of $19.14, a decrease of $0.61 (-3.09%). It also indicates that there are no analyst ratings or earnings information currently available for the company. The page is hosted by ", "url": "https://www.timothysykes.com/quote/VOR/", "source_name": "Timothy Sykes", "published_at": "2026-07-10T23:41:08", "published_display": "10 Jul 2026 23:41", "sentiment": "negative", "sentiment_pct": 41, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Vor Biopharma Inc For: 9 July By Investing.com", "summary": "This article reports on a Form 4 filing for Vor Biopharma Inc. dated July 9th. It notes that Vor Biopharma Inc. stock (VOR) experienced a -2.76% change. The content also briefly touches upon various financial market data and news headlines.", "url": "https://ca.investing.com/news/stock-market-news/form-4-vor-biopharma-inc-for-9-july-93CH-4727975", "source_name": "Investing.com Canada", "published_at": "2026-07-09T20:16:13", "published_display": "09 Jul 2026 20:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vor Biopharma (VOR) director receives 42,658 stock options at $20.10 strike", "summary": "Vor Biopharma director David Zaccardelli has been granted 42,658 stock options with an exercise price of $20.10 per share, expiring on July 6, 2036. These options will vest in 36 equal monthly installments starting August 7, 2026, contingent upon his continued service to the comp", "url": "https://www.stocktitan.net/sec-filings/VOR/form-4-vor-biopharma-inc-insider-trading-activity-8408049472cf.html", "source_name": "Stock Titan", "published_at": "2026-07-09T20:16:13", "published_display": "09 Jul 2026 20:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vor Biopharma (VOR) director submits initial Form 3 with no trades", "summary": "Vor Biopharma Inc. director David Zaccardelli has filed an initial ownership report on Form 3, indicating no reportable stock or derivative positions and no transactions. This filing serves as a baseline regulatory disclosure, establishing his initial status as a reporting person", "url": "https://www.stocktitan.net/sec-filings/VOR/form-3-vor-biopharma-inc-initial-statement-of-beneficial-ownership-62c5bb9bbd16.html", "source_name": "Stock Titan", "published_at": "2026-07-09T20:16:13", "published_display": "09 Jul 2026 20:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vor Bio adds Verona Pharma veteran David Zaccardelli to board", "summary": "Vor Bio (Nasdaq: VOR) has appointed David Zaccardelli, Pharm.D., to its Board of Directors, bringing over two decades of biopharmaceutical leadership experience. Zaccardelli previously guided Verona Pharma through FDA approval and a $10 billion acquisition by Merck, and Dova Phar", "url": "https://www.stocktitan.net/news/VOR/vor-bio-appoints-david-zaccardelli-to-board-of-p9gffysakskt.html", "source_name": "Stock Titan", "published_at": "2026-07-07T20:11:03", "published_display": "07 Jul 2026 20:11", "sentiment": "positive", "sentiment_pct": 75, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "David Zaccardelli joins Vor Biopharma (NASDAQ: VOR) board after Levin exit", "summary": "Vor Biopharma Inc. announced a change to its board of directors, with Andrew Levin, M.D., Ph.D., resigning effective July 6, 2026. David Zaccardelli, Pharm.D. was appointed as an independent Class II director to fill the vacancy, with his term extending until the 2029 annual meet", "url": "https://www.stocktitan.net/sec-filings/VOR/8-k-vor-biopharma-inc-reports-material-event-f5da009231ae.html", "source_name": "Stock Titan", "published_at": "2026-07-07T20:11:03", "published_display": "07 Jul 2026 20:11", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vor Biopharma: A Financed Autoimmune Pivot With More Substance Than The Market Realizes", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxQaTdpVHdMajQ3X2NZWlczaFdkQmNBZ0M0YU1QR2l2Y2R2OXNwZDBJNjdHaDlzazNWWEl2NmZLUVo5bDI1RE53djJiSS1lOU5pMm9fQml0aWJfVGdXdUhCZ0p2MWJabmVPRndYSEZVSG5wOVVTOEF3SHpkSEROYnowLWMyMTFfbnlMVG5NZ2Njd3Q5QkwxUTgtMmJFVFgyVmVBdlY1dkIxQjZDTkpGckpLamJFc0c4N2lfb2R1Si01dlJFVzRaRmc?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-07T18:39:05+00:00", "published_display": "07 Jul 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Vor Bio announced that on July 1, 2026, its Compensation Committee granted stock options for 71,200 shares and restricted stock units (RSUs) for 15,150 shares to 7 new employees. These grants serve as material inducements for employment, in compliance with Nasdaq Listing Rule 563", "url": "https://sg.finance.yahoo.com/news/vor-bio-reports-inducement-grant-213000385.html", "source_name": "Market source", "published_at": "2026-07-06T11:41:18", "published_display": "06 Jul 2026 11:41", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Vor Biopharma (VOR) Is Up 27.9% After Broad Russell Index Inclusion And What's Next", "summary": "Vor Biopharma (VOR) recently experienced a 27.9% stock increase following its inclusion in several Russell indexes, including the Russell 2000 and 3000. While this inclusion boosts visibility and liquidity, the company's investment narrative still hinges on clinical progress, reg", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vor/vor-biopharma/news/why-vor-biopharma-vor-is-up-279-after-broad-russell-index-in/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-05T20:39:58", "published_display": "05 Jul 2026 20:39", "sentiment": "negative", "sentiment_pct": 40, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vor Bio grants stock awards to 7 new hires under Nasdaq rule", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPUkdyb3NkLWhuQW9EMEFTS3Q2em43al85a2p2QlJxd3dYeEJ6Ykd0RkhDbDJKZWkyVTFFdEJicGh4dmlURUgxQ0YzbEZBNHlDVWlPQXZRMUtFWGNob1pEVjMwaW9sSEY3dUZWZWEwU3BGYnI4c2VYQUdOdEc0ZVlzSTNQckgtekVGRGZPRG1tLUFIbERwMFpmU09oUkFoV1E2Z2ZYNk9icUMyNkdFLWdpNVl1OGh2R2E5YU5r?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "3 Reasons Vor Biopharma (VOR) Looks Pricey On Russell Index Inclusion", "summary": "Vor Biopharma (VOR) has been added to several Russell indexes, leading to increased trading interest and a significant short-term price jump. However, the company faces skepticism due to negative shareholders' equity, a high Price-to-Book ratio compared to peers, and continued lo", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vor/vor-biopharma/news/3-reasons-vor-biopharma-vor-looks-pricey-on-russell-index-in/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-01T20:12:08", "published_display": "01 Jul 2026 20:12", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Vor Biopharma (VOR) Is Up 24.5% After Broad FTSE Russell Index Inclusion And What's Next", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxOUlZBRjBxZFVNWDNnT25Td0dtclU1RmFuZmxEbHpPeVZIV08wS2FkYjhjOVRnNS14TWRPdEZzaHNnQmpYWDBUa0JUSGI3MHhUbTIzS3VVSW9qbWpCWGZPd2J0VG1JY0w2OUdmbVJ5cU8waVR4ZXdOaGNWdVllcGF0VEhHSVJSeUI1NThEbm50aEpUZFk?oc=5", "source_name": "Market source", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vor Biopharma Inc.(NasdaqGS: VOR) added to Russell 3000E Growth Benchmark", "summary": "Vor Biopharma Inc. (NasdaqGS: VOR), a clinical-stage biotechnology company specializing in autoimmune disease treatments, has been added to the Russell 3000E Growth Benchmark. The company is actively advancing its lead drug, telitacicept, a dual-target fusion protein, through Pha", "url": "https://www.marketscreener.com/news/vor-biopharma-inc-nasdaqgs-vor-added-to-russell-3000e-growth-benchmark-ce7f5fdedf88f425", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T08:41:33", "published_display": "29 Jun 2026 08:41", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Vor Biopharma Inc. \u2013 NASDAQ:VOR", "summary": "This article provides financial data for Vor Biopharma Inc. (NASDAQ: VOR), specifically its enterprise value to EBITDA forward. It indicates the market status as closed with no trades and highlights that the data is provided by ICE Data Services and FactSet.", "url": "https://www.tradingview.com/symbols/NASDAQ-VOR/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T18:39:53", "published_display": "28 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Vor Biopharma Inc. \u2013 NASDAQ:VOR", "summary": "The article focuses on the enterprise value to EBIT forward for Vor Biopharma Inc. (NASDAQ: VOR). It appears to be a financial data point or analysis provided by TradingView, a platform offering market data and tools for financial analysis. The content primarily lists various fun", "url": "https://www.tradingview.com/symbols/NASDAQ-VOR/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T02:10:28", "published_display": "28 Jun 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vor Biopharma, Inc. Actuals & Estimates (NASDAQ:VOR)", "summary": "This article provides an overview of Vor Biopharma Inc. (NASDAQ:VOR) stock, including its current price, historical performance, analyst forecasts, and financial data. It highlights that VOR stock has recently increased but shown a yearly decrease, and discusses past earnings and", "url": "https://www.tradingview.com/symbols/NASDAQ-VOR/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T23:39:48", "published_display": "26 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vor Biopharma | 4: Statement of changes in beneficial ownership of securities-Director RA CAPITAL MANAGEMENT, L.P. - moomoo", "summary": "This document from Vor Biopharma is a Statement of Changes in Beneficial Ownership of Securities (Form 4). The filing indicates changes in the ownership holdings of Director RA CAPITAL MANAGEMENT, L.P.", "url": "https://www.moomoo.com/news/notice/306907391/vor-biopharma-4-statement-of-changes-in-beneficial-ownership-of", "source_name": "Moomoo", "published_at": "2026-06-26T17:39:48", "published_display": "26 Jun 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VOR Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Vor Biopharma Inc. (VOR) stock, including analyst price targets, historical performance, and financial data. Analysts have provided 1-year max and min estimates for the stock's price, and the article also details its past price movements, vola", "url": "https://www.tradingview.com/symbols/NASDAQ-VOR/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T17:09:56", "published_display": "25 Jun 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Vor Biopharma Inc. \u2013 NASDAQ:VOR", "summary": "This article focuses on the enterprise value to revenue forward metric for Vor Biopharma Inc. (NASDAQ: VOR). It appears to be a financial data point provided by TradingView, a financial platform offering various market tools and data. The content primarily lists the company and t", "url": "https://www.tradingview.com/symbols/NASDAQ-VOR/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T08:41:20", "published_display": "25 Jun 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vor Biopharma Inc (VOR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey concerns Vor Biopharma Inc (VOR)'s revenue breakdown. However, it states that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. Therefore, while the article provides a fram", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-vor/revenue", "source_name": "TradingKey", "published_at": "2026-06-19T01:10:18", "published_display": "19 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vor Biopharma Inc (VOR) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides a summary of Vor Biopharma Inc's (VOR) dividend and stock split history. It states that the company has distributed $0.00 in dividends over the past five years and lists a stock split event for September 17, 2025, which is specified as a 20-to-1 merger. The ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-vor/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T19:10:18", "published_display": "18 Jun 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vor Biopharma Inc (VOR) Financial Health: Profitability & Balance Sheet Analysis", "summary": "The article provides a financial health analysis of Vor Biopharma Inc (VOR) from TradingKey. It displays current stock price information, market capitalization, and indicates that key financial data points such as cash and cash equivalents, total assets, total liabilities, free c", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-vor/financial-health", "source_name": "TradingKey", "published_at": "2026-06-17T09:11:30", "published_display": "17 Jun 2026 09:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vor Biopharma Inc (VOR) Institutional Confidence", "summary": "This article from TradingKey provides an overview of institutional confidence in Vor Biopharma Inc (VOR), including its stock performance and key institutional shareholders. It lists major shareholders such as Forbion Capital Partners, Frazier Life Sciences Management, and Fideli", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-vor/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T08:39:47", "published_display": "17 Jun 2026 08:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Vor Biopharma Inc. Insider Trading Activity", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOX1d5MVpOS1drV2NqOHpfWnJzSlVkTkVWS0JReUJmNmVMejRVanRXeHkwNUtWT2Q1bnE5RU8yNXdlVDVvM2Nkb1VvZkZuSENUVDY5bUZoTF90ZmNRM3hJdE1HR1ZRRk9JMjhnLUdVZi15RkNaOFd2dm5TZHQ2aUFUSmg4REg1amttWkd4TGsxWnhQMDBGWlFpTHRFcGQyX29uSjNsMXVnUFVGNTdBdWhr?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vor Biopharma (VOR) director Fouad Namouni awarded 56,549 stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxPTDRWTDM0aWhWRUk5Z19BWEhSbFRLQ1R0UE9KT19FNjdmOHZfNzNXc29lTGNWTW1mZnNHV09FakhUR0RVTkFSVFpZRjJrUmpTbzAwa0FRY1hyRFoxdGNHS29PU25LSm5sVTMtS19DaXlCMndwX28yWlE2Z05rWU5Nak15bFJVbDdZbmZCYUY1R2NXZXJweEs4R2tFdWFUU2FHbGVoak5ldGVNV0NpV2dj?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vor Biopharma (VOR) director awarded 57,162 stock options at $14.09 strike", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOcXE2dmF4c0huamJkbXhmclFqcWNwYkRVYUsyN2U2ZE5qYlgzcEl4UEp3dWloWktBVWFNN3BnbWVodGg1Uy0wT1JwNVVKUzI5aUFrQUdJczlwQlR1dUZYdWkxaDBIUk5QUUZocVR1NXlueXdHdUQ0OGhhSmRaNDBwaUZvQTAyMTRRVjFhNGhLYVlWX3F1X0p6dnFjQWxFS0tMRUVYcG1PZ3RDcno2dDBV?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Hopeful That Vor Biopharma (NASDAQ:VOR) Will Use Its Cash Wisely", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/were-hopeful-vor-biopharma-nasdaq-122530613.html", "source_name": "Simply Wall St.", "published_at": "2026-05-15T12:25:30+00:00", "published_display": "15 May 2026 12:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Companies Like Vor Biopharma (NASDAQ:VOR) Are In A Position To Invest In Growth", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "[EFFECT] Vor Biopharma Inc. SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNVy1FN3dtQzFUTHA3bzYyNUs3bnp6WlUtQW1lRWhVbXI0dk9BQWlXc2wwTE1mTWU0c3cwQUdGYXVoZ0tia2ZfNkxlMzRLVlZ4dUJyWnAyemowaTJGcDVnTXdGbG9FaEE2VW5KUUw5VkJ2UFlWMERrcld4VVhzb3JlYWZBQXBLTGNFWmltN2dUWmhrbU5wM3cwNTBzX1M?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Does Vor Biopharma (VOR) Have the Potential to Rally 117% as Wall Street Analysts Expect?", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNVmFmY0czS3VsWDI1VHpnYlhkcU1oWVcxVzFUdG1aTjNTemc4VEhHM3g4WTFJWFc4M0M1SGplTGhjOU5xYUYxbGVzY1NWaVAyQkJuRFlnblpQZ0xhNm5vX2lCX0h4YTFWRWUtRWh5Tkd4bzZzSDBRV21LU2FCczNWcVRtenpFNHJLOEhPQlNfTDBVc3QyWUluMVRiZno3QQ?oc=5", "source_name": "Market source", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vor Biopharma: It's A Game Of Wait And See (NASDAQ:VOR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxOZ212djJQOGFIUzN6cXpvY244amNlQllmRmhya2ZYZG01dy1SVUVZOFFMZlVYWTZTN0JTZldYNkw1ejZVTVV4aWdVVVQybWhSNk9UTWtGQ2hPbU5JdGdLSTRHa2RLclRMNWcwMHFyLUdOM3hUbFYyTFhjODhDeFBOTS1VczNVSDlP?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-08T07:00:00+00:00", "published_display": "08 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ra capital sells Vor Biopharma (VOR) shares worth $14.5 million", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxOc0ZlRTE4WVpESHpBOS1kUHJFUTE3OTZORXRiOXRJc2pjM09SUVZvME9ZcnZsejhaT2d1bS1OZ0wwbF8wRmpwVjJRX2hySTNVdmhqdndaYlBINXRTUnlHQWU3Y3I5alI0YlpfTHZoeHA2OVRJQURTMGRicWVIaVlrY1NxeG9LT0hLamgxTkR5QlF1dmF0SG1ycXAwUF8zd1lndG5ZMVFsdExlckgybmp1TVdleWhjYjcta3pTWGxldXlHZw?oc=5", "source_name": "Investing.com", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vor Biopharma (VOR) Upgraded to Buy: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNZXRDVm1iMUVnd2oyUXY0NjRkWjAtLVJoYWpVeUxIaVBYbjU2T2xHWVg4NHR3Z250bVA5cG44UjVTOXpqOUdmRnhWcS1fTTNfOEd5Rk5qeXdzVWNwWllJVmRqdDlLQXNCY29WWG5kRnRYOXZIVjJvUDJUNG43bWtJazhhZ1l4M1RvM3JwXzJ1c0hpdFlIWXNGZDF0cw?oc=5", "source_name": "Market source", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Vor Biopharma (VOR) Is Up 45.6% After Telitacicept Phase 3 Win And JPMorgan Nod Has The Bull Case Changed?", "summary": "", "url": "https://news.google.com/rss/articles/CBMid0FVX3lxTE1QQTc3elFNY2p0YTdsenVkbVFYUEpxSWtfU0xhSE54TndtaFJBa1d6eDZ6cEhGanVzMkV0alRoNUNvZFZkNTNKaElFT3A2cjJvN3Z5dmdsMTY3MWFlT052Zl9OOUlic1lHT1BaZXJqSDZPVkEwZHpR?oc=5", "source_name": "Market source", "published_at": "2025-12-12T08:00:00+00:00", "published_display": "12 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vor Biopharma: J.P. Morgan Makes Bull Case After Corporate Actions Slam Stock Price (VOR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNb2NzaUltUXktNmZVMFFZc1FIMW9va3BBQnJMZlA4eG5DcGZKS1RaNXg1YjY4TS04b3RLbm5Bc3VZTHZRYkxmQldRQUNRR2ZVTU12aEU1a2lGb2dEbnQyeW9TdElhSXF0MVlYZks3b254S2dsQzlvRVhxcGdTTDRvSXNMWk15TmZHbUFrOFpVWDRvZExJWVF3bWE4dmNXcG9qYWFwZFNsa0FxcmltSjdkTGtJb3V6MnNubDFqelNB?oc=5", "source_name": "Seeking Alpha", "published_at": "2025-12-10T08:00:00+00:00", "published_display": "10 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vor Biopharma (VOR) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiUkFVX3lxTE1tRXNLLXdzdnB0MklvWUVTT2N3aWh3MkROOHFEQzJOOVVHZ0NiWC1JeG5mb0p2aGRLeW55eWMwMUNSTUJ6WnBUaEhpbHlFWHdUeWc?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T01:35:39+00:00", "published_display": "25 Apr 2025 01:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vor Biopharma (VOR) Stock Price, News & Analysis $VOR", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWEFVX3lxTE15WnNmYUZQN1FEeXlfRDVFTzlPdkpmd2NNdDRGNUVIcDh1ai01d1E4c3pSS1g5TDExV1c4d3JPdUViUXFrM05jdmVTcDVUejEzeEhnVEJBNVQ?oc=5", "source_name": "MarketBeat", "published_at": "2021-08-23T14:11:18+00:00", "published_display": "23 Aug 2021 14:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VOR Stock Price and Chart \u2014 NASDAQ:VOR", "summary": "", "url": "https://news.google.com/rss/articles/CBMiW0FVX3lxTE5JbGN0aG9nSUMyT1JzMndpUmlQZGdBVnV1cE4tSVBwbmVvR2ZTWHpwMVgxWmZfRGhiY0lVVGwzbzhtSGtPTUtfZWl2X1U1UXVyeW1RUkRvRzBpRWc?oc=5", "source_name": "TradingView", "published_at": "2021-02-04T16:02:11+00:00", "published_display": "04 Feb 2021 16:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Vor Biopharma (VOR) Stock Forum and Discussion", "summary": "This article provides a platform for discussion regarding Vor Biopharma (VOR) stock. It includes a basic overview of the company's stock performance and related financial metrics, along with sections for forum discussions, price forecasts, and news. The content primarily serves a", "url": "https://www.moomoo.com/stock/VOR-US/community?chain_id=Name1K9-3FXPhg.1kuar40&global_content=%7B%22promote_id%22%3A14282,%22sub_promote_id%22%3A29,%22f%22%3A%22www.moomoo.com%2Fca%2Fhans%2Flearn%2Fdetail-buy-call-66283-230283080%22%7D", "source_name": "Moomoo", "published_at": "2026-07-15T00:21:00", "published_display": "15 Jul 2026 00:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vor Biopharma Inc. (VOR) Stock Price | Live Quotes & Charts | NASDAQ", "summary": "This page provides live quotes and charts for Vor Biopharma Inc. (VOR) stock, showing its current price of $19.14, a decrease of $0.61 (-3.09%). It also indicates that there are no analyst ratings or earnings information currently available for the company. The page is hosted by ", "url": "https://www.timothysykes.com/quote/VOR/", "source_name": "Timothy Sykes", "published_at": "2026-07-10T23:41:08", "published_display": "10 Jul 2026 23:41", "sentiment": "negative", "sentiment_pct": 41, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Vor Biopharma Inc For: 9 July By Investing.com", "summary": "This article reports on a Form 4 filing for Vor Biopharma Inc. dated July 9th. It notes that Vor Biopharma Inc. stock (VOR) experienced a -2.76% change. The content also briefly touches upon various financial market data and news headlines.", "url": "https://ca.investing.com/news/stock-market-news/form-4-vor-biopharma-inc-for-9-july-93CH-4727975", "source_name": "Investing.com Canada", "published_at": "2026-07-09T20:16:13", "published_display": "09 Jul 2026 20:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vor Biopharma (VOR) director receives 42,658 stock options at $20.10 strike", "summary": "Vor Biopharma director David Zaccardelli has been granted 42,658 stock options with an exercise price of $20.10 per share, expiring on July 6, 2036. These options will vest in 36 equal monthly installments starting August 7, 2026, contingent upon his continued service to the comp", "url": "https://www.stocktitan.net/sec-filings/VOR/form-4-vor-biopharma-inc-insider-trading-activity-8408049472cf.html", "source_name": "Stock Titan", "published_at": "2026-07-09T20:16:13", "published_display": "09 Jul 2026 20:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vor Biopharma (VOR) director submits initial Form 3 with no trades", "summary": "Vor Biopharma Inc. director David Zaccardelli has filed an initial ownership report on Form 3, indicating no reportable stock or derivative positions and no transactions. This filing serves as a baseline regulatory disclosure, establishing his initial status as a reporting person", "url": "https://www.stocktitan.net/sec-filings/VOR/form-3-vor-biopharma-inc-initial-statement-of-beneficial-ownership-62c5bb9bbd16.html", "source_name": "Stock Titan", "published_at": "2026-07-09T20:16:13", "published_display": "09 Jul 2026 20:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vor Bio adds Verona Pharma veteran David Zaccardelli to board", "summary": "Vor Bio (Nasdaq: VOR) has appointed David Zaccardelli, Pharm.D., to its Board of Directors, bringing over two decades of biopharmaceutical leadership experience. Zaccardelli previously guided Verona Pharma through FDA approval and a $10 billion acquisition by Merck, and Dova Phar", "url": "https://www.stocktitan.net/news/VOR/vor-bio-appoints-david-zaccardelli-to-board-of-p9gffysakskt.html", "source_name": "Stock Titan", "published_at": "2026-07-07T20:11:03", "published_display": "07 Jul 2026 20:11", "sentiment": "positive", "sentiment_pct": 75, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "David Zaccardelli joins Vor Biopharma (NASDAQ: VOR) board after Levin exit", "summary": "Vor Biopharma Inc. announced a change to its board of directors, with Andrew Levin, M.D., Ph.D., resigning effective July 6, 2026. David Zaccardelli, Pharm.D. was appointed as an independent Class II director to fill the vacancy, with his term extending until the 2029 annual meet", "url": "https://www.stocktitan.net/sec-filings/VOR/8-k-vor-biopharma-inc-reports-material-event-f5da009231ae.html", "source_name": "Stock Titan", "published_at": "2026-07-07T20:11:03", "published_display": "07 Jul 2026 20:11", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vor Biopharma: A Financed Autoimmune Pivot With More Substance Than The Market Realizes", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxQaTdpVHdMajQ3X2NZWlczaFdkQmNBZ0M0YU1QR2l2Y2R2OXNwZDBJNjdHaDlzazNWWEl2NmZLUVo5bDI1RE53djJiSS1lOU5pMm9fQml0aWJfVGdXdUhCZ0p2MWJabmVPRndYSEZVSG5wOVVTOEF3SHpkSEROYnowLWMyMTFfbnlMVG5NZ2Njd3Q5QkwxUTgtMmJFVFgyVmVBdlY1dkIxQjZDTkpGckpLamJFc0c4N2lfb2R1Si01dlJFVzRaRmc?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-07T18:39:05+00:00", "published_display": "07 Jul 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Vor Bio announced that on July 1, 2026, its Compensation Committee granted stock options for 71,200 shares and restricted stock units (RSUs) for 15,150 shares to 7 new employees. These grants serve as material inducements for employment, in compliance with Nasdaq Listing Rule 563", "url": "https://sg.finance.yahoo.com/news/vor-bio-reports-inducement-grant-213000385.html", "source_name": "Market source", "published_at": "2026-07-06T11:41:18", "published_display": "06 Jul 2026 11:41", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Vor Biopharma (VOR) Is Up 27.9% After Broad Russell Index Inclusion And What's Next", "summary": "Vor Biopharma (VOR) recently experienced a 27.9% stock increase following its inclusion in several Russell indexes, including the Russell 2000 and 3000. While this inclusion boosts visibility and liquidity, the company's investment narrative still hinges on clinical progress, reg", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vor/vor-biopharma/news/why-vor-biopharma-vor-is-up-279-after-broad-russell-index-in/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-05T20:39:58", "published_display": "05 Jul 2026 20:39", "sentiment": "negative", "sentiment_pct": 40, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vor Bio grants stock awards to 7 new hires under Nasdaq rule", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPUkdyb3NkLWhuQW9EMEFTS3Q2em43al85a2p2QlJxd3dYeEJ6Ykd0RkhDbDJKZWkyVTFFdEJicGh4dmlURUgxQ0YzbEZBNHlDVWlPQXZRMUtFWGNob1pEVjMwaW9sSEY3dUZWZWEwU3BGYnI4c2VYQUdOdEc0ZVlzSTNQckgtekVGRGZPRG1tLUFIbERwMFpmU09oUkFoV1E2Z2ZYNk9icUMyNkdFLWdpNVl1OGh2R2E5YU5r?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "3 Reasons Vor Biopharma (VOR) Looks Pricey On Russell Index Inclusion", "summary": "Vor Biopharma (VOR) has been added to several Russell indexes, leading to increased trading interest and a significant short-term price jump. However, the company faces skepticism due to negative shareholders' equity, a high Price-to-Book ratio compared to peers, and continued lo", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vor/vor-biopharma/news/3-reasons-vor-biopharma-vor-looks-pricey-on-russell-index-in/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-01T20:12:08", "published_display": "01 Jul 2026 20:12", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Vor Biopharma (VOR) Is Up 24.5% After Broad FTSE Russell Index Inclusion And What's Next", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxOUlZBRjBxZFVNWDNnT25Td0dtclU1RmFuZmxEbHpPeVZIV08wS2FkYjhjOVRnNS14TWRPdEZzaHNnQmpYWDBUa0JUSGI3MHhUbTIzS3VVSW9qbWpCWGZPd2J0VG1JY0w2OUdmbVJ5cU8waVR4ZXdOaGNWdVllcGF0VEhHSVJSeUI1NThEbm50aEpUZFk?oc=5", "source_name": "Market source", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vor Biopharma Inc.(NasdaqGS: VOR) added to Russell 3000E Growth Benchmark", "summary": "Vor Biopharma Inc. (NasdaqGS: VOR), a clinical-stage biotechnology company specializing in autoimmune disease treatments, has been added to the Russell 3000E Growth Benchmark. The company is actively advancing its lead drug, telitacicept, a dual-target fusion protein, through Pha", "url": "https://www.marketscreener.com/news/vor-biopharma-inc-nasdaqgs-vor-added-to-russell-3000e-growth-benchmark-ce7f5fdedf88f425", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T08:41:33", "published_display": "29 Jun 2026 08:41", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Vor Biopharma Inc. \u2013 NASDAQ:VOR", "summary": "This article provides financial data for Vor Biopharma Inc. (NASDAQ: VOR), specifically its enterprise value to EBITDA forward. It indicates the market status as closed with no trades and highlights that the data is provided by ICE Data Services and FactSet.", "url": "https://www.tradingview.com/symbols/NASDAQ-VOR/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T18:39:53", "published_display": "28 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Vor Biopharma Inc. \u2013 NASDAQ:VOR", "summary": "The article focuses on the enterprise value to EBIT forward for Vor Biopharma Inc. (NASDAQ: VOR). It appears to be a financial data point or analysis provided by TradingView, a platform offering market data and tools for financial analysis. The content primarily lists various fun", "url": "https://www.tradingview.com/symbols/NASDAQ-VOR/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T02:10:28", "published_display": "28 Jun 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vor Biopharma, Inc. Actuals & Estimates (NASDAQ:VOR)", "summary": "This article provides an overview of Vor Biopharma Inc. (NASDAQ:VOR) stock, including its current price, historical performance, analyst forecasts, and financial data. It highlights that VOR stock has recently increased but shown a yearly decrease, and discusses past earnings and", "url": "https://www.tradingview.com/symbols/NASDAQ-VOR/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T23:39:48", "published_display": "26 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vor Biopharma | 4: Statement of changes in beneficial ownership of securities-Director RA CAPITAL MANAGEMENT, L.P. - moomoo", "summary": "This document from Vor Biopharma is a Statement of Changes in Beneficial Ownership of Securities (Form 4). The filing indicates changes in the ownership holdings of Director RA CAPITAL MANAGEMENT, L.P.", "url": "https://www.moomoo.com/news/notice/306907391/vor-biopharma-4-statement-of-changes-in-beneficial-ownership-of", "source_name": "Moomoo", "published_at": "2026-06-26T17:39:48", "published_display": "26 Jun 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VOR Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Vor Biopharma Inc. (VOR) stock, including analyst price targets, historical performance, and financial data. Analysts have provided 1-year max and min estimates for the stock's price, and the article also details its past price movements, vola", "url": "https://www.tradingview.com/symbols/NASDAQ-VOR/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T17:09:56", "published_display": "25 Jun 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Vor Biopharma Inc. \u2013 NASDAQ:VOR", "summary": "This article focuses on the enterprise value to revenue forward metric for Vor Biopharma Inc. (NASDAQ: VOR). It appears to be a financial data point provided by TradingView, a financial platform offering various market tools and data. The content primarily lists the company and t", "url": "https://www.tradingview.com/symbols/NASDAQ-VOR/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T08:41:20", "published_display": "25 Jun 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vor Biopharma Inc (VOR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey concerns Vor Biopharma Inc (VOR)'s revenue breakdown. However, it states that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. Therefore, while the article provides a fram", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-vor/revenue", "source_name": "TradingKey", "published_at": "2026-06-19T01:10:18", "published_display": "19 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vor Biopharma Inc (VOR) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides a summary of Vor Biopharma Inc's (VOR) dividend and stock split history. It states that the company has distributed $0.00 in dividends over the past five years and lists a stock split event for September 17, 2025, which is specified as a 20-to-1 merger. The ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-vor/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T19:10:18", "published_display": "18 Jun 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vor Biopharma Inc (VOR) Financial Health: Profitability & Balance Sheet Analysis", "summary": "The article provides a financial health analysis of Vor Biopharma Inc (VOR) from TradingKey. It displays current stock price information, market capitalization, and indicates that key financial data points such as cash and cash equivalents, total assets, total liabilities, free c", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-vor/financial-health", "source_name": "TradingKey", "published_at": "2026-06-17T09:11:30", "published_display": "17 Jun 2026 09:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vor Biopharma Inc (VOR) Institutional Confidence", "summary": "This article from TradingKey provides an overview of institutional confidence in Vor Biopharma Inc (VOR), including its stock performance and key institutional shareholders. It lists major shareholders such as Forbion Capital Partners, Frazier Life Sciences Management, and Fideli", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-vor/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T08:39:47", "published_display": "17 Jun 2026 08:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Vor Biopharma Inc. Insider Trading Activity", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOX1d5MVpOS1drV2NqOHpfWnJzSlVkTkVWS0JReUJmNmVMejRVanRXeHkwNUtWT2Q1bnE5RU8yNXdlVDVvM2Nkb1VvZkZuSENUVDY5bUZoTF90ZmNRM3hJdE1HR1ZRRk9JMjhnLUdVZi15RkNaOFd2dm5TZHQ2aUFUSmg4REg1amttWkd4TGsxWnhQMDBGWlFpTHRFcGQyX29uSjNsMXVnUFVGNTdBdWhr?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vor Biopharma (VOR) director Fouad Namouni awarded 56,549 stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxPTDRWTDM0aWhWRUk5Z19BWEhSbFRLQ1R0UE9KT19FNjdmOHZfNzNXc29lTGNWTW1mZnNHV09FakhUR0RVTkFSVFpZRjJrUmpTbzAwa0FRY1hyRFoxdGNHS29PU25LSm5sVTMtS19DaXlCMndwX28yWlE2Z05rWU5Nak15bFJVbDdZbmZCYUY1R2NXZXJweEs4R2tFdWFUU2FHbGVoak5ldGVNV0NpV2dj?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vor Biopharma (VOR) director awarded 57,162 stock options at $14.09 strike", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOcXE2dmF4c0huamJkbXhmclFqcWNwYkRVYUsyN2U2ZE5qYlgzcEl4UEp3dWloWktBVWFNN3BnbWVodGg1Uy0wT1JwNVVKUzI5aUFrQUdJczlwQlR1dUZYdWkxaDBIUk5QUUZocVR1NXlueXdHdUQ0OGhhSmRaNDBwaUZvQTAyMTRRVjFhNGhLYVlWX3F1X0p6dnFjQWxFS0tMRUVYcG1PZ3RDcno2dDBV?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Hopeful That Vor Biopharma (NASDAQ:VOR) Will Use Its Cash Wisely", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/were-hopeful-vor-biopharma-nasdaq-122530613.html", "source_name": "Simply Wall St.", "published_at": "2026-05-15T12:25:30+00:00", "published_display": "15 May 2026 12:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Companies Like Vor Biopharma (NASDAQ:VOR) Are In A Position To Invest In Growth", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[EFFECT] Vor Biopharma Inc. SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNVy1FN3dtQzFUTHA3bzYyNUs3bnp6WlUtQW1lRWhVbXI0dk9BQWlXc2wwTE1mTWU0c3cwQUdGYXVoZ0tia2ZfNkxlMzRLVlZ4dUJyWnAyemowaTJGcDVnTXdGbG9FaEE2VW5KUUw5VkJ2UFlWMERrcld4VVhzb3JlYWZBQXBLTGNFWmltN2dUWmhrbU5wM3cwNTBzX1M?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Vor Biopharma (VOR) Have the Potential to Rally 117% as Wall Street Analysts Expect?", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNVmFmY0czS3VsWDI1VHpnYlhkcU1oWVcxVzFUdG1aTjNTemc4VEhHM3g4WTFJWFc4M0M1SGplTGhjOU5xYUYxbGVzY1NWaVAyQkJuRFlnblpQZ0xhNm5vX2lCX0h4YTFWRWUtRWh5Tkd4bzZzSDBRV21LU2FCczNWcVRtenpFNHJLOEhPQlNfTDBVc3QyWUluMVRiZno3QQ?oc=5", "source_name": "Market source", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vor Biopharma: It's A Game Of Wait And See (NASDAQ:VOR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxOZ212djJQOGFIUzN6cXpvY244amNlQllmRmhya2ZYZG01dy1SVUVZOFFMZlVYWTZTN0JTZldYNkw1ejZVTVV4aWdVVVQybWhSNk9UTWtGQ2hPbU5JdGdLSTRHa2RLclRMNWcwMHFyLUdOM3hUbFYyTFhjODhDeFBOTS1VczNVSDlP?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-08T07:00:00+00:00", "published_display": "08 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ra capital sells Vor Biopharma (VOR) shares worth $14.5 million", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxOc0ZlRTE4WVpESHpBOS1kUHJFUTE3OTZORXRiOXRJc2pjM09SUVZvME9ZcnZsejhaT2d1bS1OZ0wwbF8wRmpwVjJRX2hySTNVdmhqdndaYlBINXRTUnlHQWU3Y3I5alI0YlpfTHZoeHA2OVRJQURTMGRicWVIaVlrY1NxeG9LT0hLamgxTkR5QlF1dmF0SG1ycXAwUF8zd1lndG5ZMVFsdExlckgybmp1TVdleWhjYjcta3pTWGxldXlHZw?oc=5", "source_name": "Investing.com", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vor Biopharma (VOR) Upgraded to Buy: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNZXRDVm1iMUVnd2oyUXY0NjRkWjAtLVJoYWpVeUxIaVBYbjU2T2xHWVg4NHR3Z250bVA5cG44UjVTOXpqOUdmRnhWcS1fTTNfOEd5Rk5qeXdzVWNwWllJVmRqdDlLQXNCY29WWG5kRnRYOXZIVjJvUDJUNG43bWtJazhhZ1l4M1RvM3JwXzJ1c0hpdFlIWXNGZDF0cw?oc=5", "source_name": "Market source", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vor Biopharma (VOR) Is Up 45.6% After Telitacicept Phase 3 Win And JPMorgan Nod Has The Bull Case Changed?", "summary": "", "url": "https://news.google.com/rss/articles/CBMid0FVX3lxTE1QQTc3elFNY2p0YTdsenVkbVFYUEpxSWtfU0xhSE54TndtaFJBa1d6eDZ6cEhGanVzMkV0alRoNUNvZFZkNTNKaElFT3A2cjJvN3Z5dmdsMTY3MWFlT052Zl9OOUlic1lHT1BaZXJqSDZPVkEwZHpR?oc=5", "source_name": "Market source", "published_at": "2025-12-12T08:00:00+00:00", "published_display": "12 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vor Biopharma: J.P. Morgan Makes Bull Case After Corporate Actions Slam Stock Price (VOR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNb2NzaUltUXktNmZVMFFZc1FIMW9va3BBQnJMZlA4eG5DcGZKS1RaNXg1YjY4TS04b3RLbm5Bc3VZTHZRYkxmQldRQUNRR2ZVTU12aEU1a2lGb2dEbnQyeW9TdElhSXF0MVlYZks3b254S2dsQzlvRVhxcGdTTDRvSXNMWk15TmZHbUFrOFpVWDRvZExJWVF3bWE4dmNXcG9qYWFwZFNsa0FxcmltSjdkTGtJb3V6MnNubDFqelNB?oc=5", "source_name": "Seeking Alpha", "published_at": "2025-12-10T08:00:00+00:00", "published_display": "10 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vor Biopharma (VOR) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiUkFVX3lxTE1tRXNLLXdzdnB0MklvWUVTT2N3aWh3MkROOHFEQzJOOVVHZ0NiWC1JeG5mb0p2aGRLeW55eWMwMUNSTUJ6WnBUaEhpbHlFWHdUeWc?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T01:35:39+00:00", "published_display": "25 Apr 2025 01:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vor Biopharma (VOR) Stock Price, News & Analysis $VOR", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWEFVX3lxTE15WnNmYUZQN1FEeXlfRDVFTzlPdkpmd2NNdDRGNUVIcDh1ai01d1E4c3pSS1g5TDExV1c4d3JPdUViUXFrM05jdmVTcDVUejEzeEhnVEJBNVQ?oc=5", "source_name": "MarketBeat", "published_at": "2021-08-23T14:11:18+00:00", "published_display": "23 Aug 2021 14:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VOR Stock Price and Chart \u2014 NASDAQ:VOR", "summary": "", "url": "https://news.google.com/rss/articles/CBMiW0FVX3lxTE5JbGN0aG9nSUMyT1JzMndpUmlQZGdBVnV1cE4tSVBwbmVvR2ZTWHpwMVgxWmZfRGhiY0lVVGwzbzhtSGtPTUtfZWl2X1U1UXVyeW1RUkRvRzBpRWc?oc=5", "source_name": "TradingView", "published_at": "2021-02-04T16:02:11+00:00", "published_display": "04 Feb 2021 16:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 92, "total_relevant": 47, "sentiment_summary": {"positive": 8, "negative": 4, "neutral": 35, "score": 53, "total": 47, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 82, "events": [{"event": "general", "label": "Market update", "weight": 15.9, "count": 27}, {"event": "earnings", "label": "Earnings", "weight": 5.5, "count": 12}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.65, "count": 3}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}], "positive_events": 8, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 19.14, "latest_week": "2026-07-10", "one_week_move": -7.0, "four_week_move": 33.3, "twelve_week_move": 15.4, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.191941, "market_dynamics_buy_signal": false, "relative_strength": -23.5764, "fair_value_gap": -28.2, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 40.7279, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-7.0% over one week, +33.3% over four weeks, trend active, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 62, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 10}, {"label": "Stock Titan", "count": 10}, {"label": "TradingView", "count": 7}, {"label": "TradingKey", "count": 4}, {"label": "Seeking Alpha", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "Moomoo", "count": 2}, {"label": "Simply Wall Street", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 39}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 27}, {"label": "Earnings", "count": 12}, {"label": "Balance sheet", "count": 3}, {"label": "Deals and strategy", "count": 2}, {"label": "Analyst action", "count": 2}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "82/100 classification confidence."}, {"label": "Company focus", "value": "39", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "3", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-7.0% over one week, +33.3% over four weeks, trend active, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Vor Biopharma (VOR) Stock Forum and Discussion"}], "updated_at": "2026-07-16T00:37:32.606780+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}